MDXG Jan 2021 1.000 put

OPR - OPR Delayed Price. Currency in USD
0.3000
+0.3000 (+0.00%)
As of 4:53PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3000
Open0.4900
Bid0.3000
Ask1.0000
Strike1.00
Expire Date2021-01-15
Day's Range0.3000 - 0.3000
Contract RangeN/A
Volume110
Open Interest300
  • GlobeNewswire

    MiMedx Announces Filing of 2020 First Quarter Form 10-Q

    Company Now Caught Up in Financial Reporting First Quarter Net Sales of $61.7 million MARIETTA, Ga., July 06, 2020 -- MiMedx Group, Inc. (OTC.

  • GlobeNewswire

    MiMedx Announces Filing of 2019 Annual Report

    Annual Report on Form 10-K includes Audited Financial Results for 2019 Transition to Revenue Recognition on an “As-Shipped” Basis Reflects Improved Internal Control Environment.

  • GlobeNewswire

    MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings, consisting of an equity financing pursuant to a Securities Purchase Agreement with an entity controlled by EW Healthcare Partners and certain funds managed by Hayfin Capital Management LLP (“Hayfin”), and a debt financing pursuant to a Loan Agreement with Hayfin. As part of the transaction, EW Healthcare Partners has designated Martin P. Sutter and William A. Hawkins III to serve on the Company’s board as preferred directors.

  • Republican lawmakers criticize Democrats for telling 5 public companies to return small-business loans
    MarketWatch

    Republican lawmakers criticize Democrats for telling 5 public companies to return small-business loans

    Republican members of a new watchdog panel on Wednesday push back against their Democratic colleagues’ demand that five public companies return emergency loans meant for small businesses hurt by the coronavirus crisis.

  • Congressional committee demands these 5 public companies return coronavirus loans meant for small businesses
    MarketWatch

    Congressional committee demands these 5 public companies return coronavirus loans meant for small businesses

    A congressional committee tasked with overseeing coronavirus stimulus funds sent letters Friday afternoon to five public companies that took out Paycheck Protection Program loans demanding they repay the funds

  • GlobeNewswire

    MiMedx Provides Update on Payment Protection Program Loan

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it is repaying the Payment Protection Program (PPP) Loan received through its application to the Federal relief effort. As announced previously, the funds enabled the Company to maintain full employment during a time of widespread uncertainty, producing skin-graft products for patients with serious wounds and burns. Similar to other companies, including those operating in the health care sector, the Company’s business has been negatively impacted by the COVID-19 pandemic.

  • GlobeNewswire

    MiMedx Announces Appointment of William L. Phelan as Chief Accounting Officer

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the appointment of William L. Phelan as Senior Vice President and Chief Accounting Officer, effective May 1, 2020. Mr. Phelan is a highly accomplished accounting professional with more than 25 years of experience building, leading and advising companies, and brings strong knowledge of financial reporting requirements and internal controls to the Company’s financial management team.

  • GlobeNewswire

    MiMedx Announces Additional Access to Capital and Financing

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has received notice from Bank of America that its application for a Paycheck Protection Program loan (a “PPP Loan”) under the CARES Act has been approved. The Company expects to receive the funds from the PPP Loan by the end of the month. In addition, the Company has agreed to terms for an amendment to its Loan Agreement, dated as of June 10, 2019, with Blue Torch Finance LLC (“Blue Torch”), to modify certain covenant terms in the original Term Loan Facility.

  • GlobeNewswire

    MiMedx Announces Settlement of VA Pricing Investigation

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Department of Justice (the “DOJ”), resolving an investigation concerning the accuracy of commercial pricing disclosures to the United States Department of Veterans Affairs (the “VA”) for one of the Company’s products in connection with the Company’s Federal Supply Schedule contract, and a related qui tam action filed in Minnesota. The Company self-disclosed the matter to the VA Office of Inspector General (VA-OIG) in November 2018, prior to its knowledge of the qui tam suit or any underlying government investigation and, as DOJ acknowledged in the settlement agreement, the Company cooperated with the government’s investigation into the matter.

  • MiMedx Names Peter M. Carlson as Chief Financial Officer
    PR Newswire

    MiMedx Names Peter M. Carlson as Chief Financial Officer

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Peter M. Carlson, Executive Vice President of Finance, has been named as the Company's Chief Financial Officer, effective immediately.

  • MiMedx Announces Filing of 2018 Annual Report
    PR Newswire

    MiMedx Announces Filing of 2018 Annual Report

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its 2018 Annual Report, which includes the Company's audited consolidated statements of operations, and stockholders' equity and cash flows for the years ended December 31, 2018 and 2017, which the Company did not previously file, and for the year ended December 31, 2016, which the Company has restated.

  • GuruFocus.com

    Baillie Gifford Takes Aim at Stock Lending and Short Sellers

    The asset manager is unconvinced of its value to price discovery Continue reading...

  • MiMedx Announces Addition of Peter M. Carlson
    PR Newswire

    MiMedx Announces Addition of Peter M. Carlson

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Peter M. Carlson as Executive Vice President, Finance, effective December 16, 2019. Mr. Carlson brings more than thirty years of comprehensive financial expertise having held positions as a Fortune 50 principal accounting officer and Big Five audit partner, as well as a senior Finance executive. He will be assisting the Company in the transition of financial duties with the departure of former Interim Chief Financial Officer, Edward J. Borkowski.

  • MiMedx Provides Update Regarding Timing of Restatement
    PR Newswire

    MiMedx Provides Update Regarding Timing of Restatement

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it expects to file its annual report on Form 10-K for the years ended December 31, 2018, 2017 and 2016 in early 2020.

  • Reuters

    UPDATE 1-Ex-CEO, COO of biotech firm MiMedx charged with securities fraud

    Two former executives of biotech company MiMedx Group Inc were criminally charged on Tuesday with fraudulently inflating the company's revenue. Former MiMedx Chief Executive Parker Petit and former Chief Operating Officer William Taylor were charged with securities fraud and conspiracy in an indictment in Manhattan federal court. "Pete Petit adamantly denies the charges leveled against him today, and he will vigorously defend himself in court," Petit' s lawyer, Eric Bruce, said in a statement.

  • Reuters

    Ex-CEO, COO of biotech firm MiMedx charged with securities fraud

    Two former executives of biotech company MiMedx Group Inc <MDXG.PK> were criminally charged on Tuesday with fraudulently inflating the company's revenue. Former MiMedx Chief Executive Parker Petit and former Chief Operating Officer William Taylor were charged with securities fraud and conspiracy in an indictment in Manhattan federal court. "Pete Petit adamantly denies the charges leveled against him today, and he will vigorously defend himself in court," Petit' s lawyer, Eric Bruce, said in a statement.

  • MiMedx Announces Securities and Exchange Commission Settlement
    PR Newswire

    MiMedx Announces Securities and Exchange Commission Settlement

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Securities and Exchange Commission (the "SEC"), resolving a previously disclosed investigation into the Company's financial accounting practices.

  • MiMedx Names William "Butch" Hulse as General Counsel and Secretary
    PR Newswire

    MiMedx Names William "Butch" Hulse as General Counsel and Secretary

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of William "Butch" Hulse as its new General Counsel and Secretary, effective December 2, 2019. With more than twenty years' experience in large law firms and life sciences organizations, Mr. Hulse brings to MiMedx legal, risk management, compliance and operational expertise and a track record of success.

  • PR Newswire

    MiMedx Announces Resignation of Board Member

    MARIETTA, Ga., Sept. 20, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Luis A. Aguilar has notified the Company of his resignation from the Board of Directors. Dr. Kathleen Behrens Wilsey, Chair of the MiMedx Board of Directors, stated, "On behalf of the Board and the Company, we thank Luis for his commitment and contributions.

  • PR Newswire

    MiMedx Announces Agreement Regarding 2019 and 2020 Shareholder Meetings

    MARIETTA, Ga. , Aug. 8, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics ...